FDA Lifts Ban but Full Review Pending
The US has reversed its 2022 ban on Juul products, one of the nation’s leading e-cigarette companies. The FDA, which initially banned Juul due to rising teenage vaping rates, clarified that this reversal does not authorize Juul’s products for sale; a full review is still pending. Juul’s products will remain available during this period.
Juul’s response and FDA’s reasoning
In a statement, Juul expressed appreciation for the FDA’s decision and commitment to working with the agency for marketing authorization. The FDA stated the reversal was influenced by new case law and additional information provided by Juul. All e-cigarette products must have FDA authorization to be legally marketed.
Concerns over teenage vaping
Founded in California in 2015, Juul promoted itself as a healthier alternative to traditional cigarettes. However, high nicotine levels and marketing strategies targeting youth led to a surge in teenage use. Critics cited colorful packaging, varied flavors, and young models in campaigns. In 2022, the FDA noted Juul’s insufficient evidence of public health compliance and harmful chemicals in e-liquid pods.
Legal settlements
Juul faced over 5,000 US lawsuits alleging it targeted teenagers and agreed to pay hundreds of millions to end a review of its advertising practices. Despite these controversies, Juul remains a significant player in the e-cigarette market, awaiting the FDA’s full review for future authorization.
